About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4439300
Allelic
Composition
Tg(CAG-lacZ,-SV40)#Bcv/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• recombinant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre (AdCre) are delivered to the ovarian surface epithelium (OSE) in vivo via intrabursal injection (J:158388)
• with a median survival of 113 days after injection (J:158388)
• decreased survival time in mice treated with exogenous 17beta-estradiol (E2) (50 vs. 113 days after AdCre) (J:158388)
• recombinant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre (AdCre) are delivered to the ovarian surface epithelium (OSE) in vivo via intrabursal injection (J:158388)
• with a median survival of 113 days after injection (J:158388)
• decreased survival time in mice treated with exogenous 17beta-estradiol (E2) (50 vs. 113 days after AdCre) (J:158388)

tumorigenesis
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment (J:158388)
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment (J:158388)
• tumors from P4 treatment have a more diffuse pattern and a higher incidence of zellballen (J:158388)
• tumors from E2-treated mice display a more diffuse appearance, abundant surface papillae, and large areas of necrosis (J:158388)
• tumors from P4 treatment have a more diffuse pattern and a higher incidence of zellballen (J:158388)
• tumors from E2-treated mice display a more diffuse appearance, abundant surface papillae, and large areas of necrosis (J:158388)
• E2 treatment accelerates tumor onset (J:158388)
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment (J:158388)
• E2 treatment accelerates tumor onset (J:158388)
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment (J:158388)
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase (J:158388)
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations (J:158388)
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase (J:158388)
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations (J:158388)
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8) (J:158388)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct (J:158388)
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8) (J:158388)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas (J:158388)
• decreased incidence of ovarian neoplasms (64 vs. 82% in controls) in progesterone (P4)-treated mice (n=11) (J:158388)
• decreased incidence of ovarian neoplasms (64 vs. 82% in controls) in progesterone (P4)-treated mice (n=11) (J:158388)

homeostasis/metabolism
• peritoneal ascites with volumes ranging from 0.5-7.5 ml in 64% of the mice (J:158388)
• accumulation of ascites and adhesions in the abdomen in one mouse without ovarian tumor (out of 11 mice) (J:158388)
• E2 treatment decrease the incidence of peritoneal ascites accumulation (J:158388)
• E2 treatment decrease the incidence of peritoneal ascites accumulation (J:158388)
• peritoneal ascites with volumes ranging from 0.5-7.5 ml in 64% of the mice (J:158388)
• accumulation of ascites and adhesions in the abdomen in one mouse without ovarian tumor (out of 11 mice) (J:158388)

muscle
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy (J:158388)

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:158388


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory